Abdullah Hayder Flaih

Mr. Abdullah Hayder Flaih

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2025 in Annals of Thoracic Surgery Short Reports
Verified
Journal Article
Open access
AFAbdullah Hayder Flaih
Abdullah Hayder Flaih
DSDarya Nadir Saeed
Darya Nadir Saeed
AFAbdullah Hayder Flaih
Abdullah Hayder Flaih
Use of coronary artery bypass for mitral valve repair in ischemic mitral regurgitation remains controversial. We present a case of a 52-year-old man with significant ischemic mitral regurgitation and coronary artery disease who underwent mitral valve repair and coronary artery bypass grafting using a periareolar technique. The procedure was successful, with early extubation and discharge on postoperative day 4. This minimally invasive approach facilitated successful repair while reducing surgical stress and enhancing recovery. Postoperative echocardiography confirmed the mitral valve's competence. This case highlights the viability of the periareolar approach for combined mitral valve repair and coronary artery bypass grafting.

24 December 2025 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
AFAbdullah Hayder Flaih
Abdullah Hayder Flaih
DSDarya Nadir Saeed
Darya Nadir Saeed
AFAbdullah Hayder Flaih
Abdullah Hayder Flaih
MBMarwan Abdullah Barzani
Marwan Abdullah Barzani
Background: Surgical urgency in minimally invasive coronary artery bypass grafting (MICS-CABG) is associated with increased perioperative risk. This study evaluates the impact of surgical urgency on early postoperative outcomes in patients undergoing isolated MICS-CABG. Methods: A retrospective cohort study was conducted at Shar Hospital, Erbil, Iraq, including 311 patients who underwent isolated MICS-CABG between September 2021 and December 2024. Patients were classified as elective group ( n = 285) and urgent group ( n = 26) according to Society of Thoracic Surgeons criteria. Baseline demographics, intraoperative variables, and early postoperative outcomes were compared using appropriate statistical tests with a significance level of p < 0.05. Results: Baseline characteristics, including, gender, and body mass index, showed no significant differences between elective and urgent groups. However, the urgent group had significantly lower preoperative left ventricular ejection fraction (49.2% ± 12.0 vs. 53.8% ± 10.0, p = 0.032) and higher preoperative serum creatinine levels (1.59 ± 1.58 vs. 1.19 ± 1.94 mg/dL, p = 0.008). Intraoperatively, urgent patients required more vasopressor support (adrenaline: 26.9% vs. 10.2%, p = 0.020; noradrenaline: 73.1% vs. 40.7%, p = 0.001). Postoperatively, urgent cases had higher serum creatinine (1.86 ± 1.79 vs. 1.14 ± 0.58 mg/dL, p = 0.037) and more frequent incidence of acute respiratory failure in urgent group (39.1% vs. 17.5%, p = 0.023). Conclusions: Urgent MICS-CABG was associated with increased vasopressor use, renal dysfunction, and respiratory complications. Trial registration: Not applicable.

12 May 2026 in Immuno
Verified
Journal Article
Open access
PDF file
SSshukur smail
shukur smail
AFAbdullah Hayder Flaih
Abdullah Hayder Flaih
BIBlnd Ismail
Blnd Ismail
AAAkhter Ahmed Ahmed
Akhter Ahmed Ahmed
ABAhmed Abdulrazzaq Bapir
Ahmed Abdulrazzaq Bapir
Christer JansonChrister Janson
Christer Janson
Living therapies, including chimeric antigen receptor T (CAR-T) cells, oncolytic viruses (OVs), and bacteria-based platforms, are emerging as promising approaches in cancer treatment because they can directly target tumors and modulate anti-tumor immunity. This narrative review summarizes current knowledge on these therapies, focusing on their mechanisms of action, therapeutic applications, major limitations, and recent advances in genetic engineering, synthetic biology, and delivery systems. CAR-T cell therapy has shown substantial clinical success in hematological malignancies through the genetic redirection of T cells against tumor-associated antigens, although its efficacy in solid tumors remains limited by antigen heterogeneity and the immunosuppressive tumor microenvironment (TME). OVs selectively infect and lyse malignant cells while also stimulating local and systemic immune responses, and engineered OVs may further enhance therapeutic activity by reshaping the TME. Bacteria-based therapies exploit the natural tumor-targeting ability of selected strains, particularly in hypoxic regions, to deliver therapeutic agents and activate immune responses. Despite encouraging progress, safety concerns, immune-related barriers, and tumor complexity remain major challenges. Overall, integrating living therapies with modern biotechnological advances and existing treatment modalities may support more personalized and synergistic strategies for cancer management.